{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02745717: Phase 4 Interventional Completed Severe Aplastic Anemia
(2016)
Source URL:
First approved in 2020
Source:
CURESTEM CELL HEALER C5 by DNK CORPORATION LTD.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333E
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333E
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Air Purifying Agent by Jiangsu Shenying Information Technology Co. Ltd.
(2020)
Source URL:
First approved in 2020
Source:
Air Purifying Agent by Jiangsu Shenying Information Technology Co. Ltd.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Homeopathic Moon drops by Historical Remedies LLP
(2020)
Source URL:
First approved in 2020
Source:
Homeopathic Moon drops by Historical Remedies LLP
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 355
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 355
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02054455: Phase 4 Interventional Completed Gastrointestinal Symptoms
(2012)
Source URL:
First approved in 2020
Source:
BACICAP PROBIOTIC by NATIONAL BIO GREEN SCIENCES LIMITED LIABILTY COMPANY
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333E
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class:
STRUCTURALLY DIVERSE